Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system

Biological Psychiatry
Roberto CiccocioppoMarkus Heilig

Abstract

Activation of the NOP receptor by its endogenous ligand nociceptin/orphanin FQ reduces ethanol intake in genetically selected alcohol preferring Marchigian Sardinian alcohol preferring (msP) rats. Here we evaluated whether buprenorphine, a partial agonist at micro-opioid and NOP receptors, would reduce ethanol consumption in msP rats via activation of NOP receptors. Marchigian Sardinian alcohol preferring rats trained to drink 10% alcohol 2 hours/day were injected with buprenorphine (.03, .3, 3.0, or 6.0 mg/kg intraperitoneally [IP]) 90 min before access to ethanol. Similar to prototypical micro-agonists, the two lowest doses of buprenorphine significantly increased ethanol consumption (p < .01); in contrast, the two highest doses reduced it (p < .05). Pretreatment with naltrexone (.25 mg/kg IP) prevented the increase of ethanol intake induced by .03 mg/kg of buprenorphine (p < .001) but did not affect the inhibition of ethanol drinking induced by 3.0 mg/kg of buprenorphine. Conversely, pretreatment with the selective NOP receptor antagonist UFP-101 (10.0 or 20.0 microg/rat) abolished the suppression of ethanol drinking by 3.0 mg/kg of buprenorphine. Buprenorphine has dualistic effects on ethanol drinking; low doses increase al...Continue Reading

References

Aug 1, 1977·British Journal of Pharmacology·A CowanI R Macfarlane
Mar 1, 1991·British Journal of Addiction·D Stastny, M Potter
Feb 1, 1990·Drug and Alcohol Dependence·T R KostenH D Kleber
Jun 1, 1990·The American Journal of Psychiatry·A RoyM Linnoila
Jan 1, 1987·Journal of Substance Abuse Treatment·W K BickelJ H Lowinson
Nov 1, 1986·Acta Anaesthesiologica Scandinavica·R Y GundersenG Narverud
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jun 1, 1987·Archives of General Psychiatry·B J RounsavilleR E Meyer
Jan 1, 1986·The American Journal of Drug and Alcohol Abuse·D E HuntL Truitt
Jan 1, 1985·Pharmacology, Biochemistry, and Behavior·H H Samson, T F Doyle
Nov 1, 1985·Archives of General Psychiatry·M A Schuckit
Nov 1, 1985·Archives of General Psychiatry·M N HesselbrockJ J Keener
May 1, 1974·Pharmacology, Biochemistry, and Behavior·J D Sinclair
Jun 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·J MagnanH W Kosterlitz
Jul 1, 1980·British Journal of Pharmacology·M B Tyers
Oct 5, 1984·Science·A J Ruttenber, J L Luke
Dec 1, 1983·Pharmacology, Biochemistry, and Behavior·A MartinT P Oei
Oct 1, 1993·Alcoholism, Clinical and Experimental Research·C L HubbellL D Reid
May 1, 1996·Archives of General Psychiatry·W LingC J Klett
Jul 1, 1996·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·R AgabioG Colombo
Nov 1, 1996·Neuroscience·J S MogilD K Grandy
Jan 1, 1997·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·C LobinaG Colombo
Sep 1, 1993·Harvard Review of Psychiatry·N K MelloB L Holman
Feb 10, 1999·Psychopharmacology·R CiccocioppoM Massi
Feb 19, 1999·Journal of Substance Abuse Treatment·R Z Litten, J P Allen
Feb 19, 1999·Journal of Substance Abuse Treatment·G Ottomanelli
Mar 17, 1999·Biochemical Pharmacology·M KingG W Pasternak
Sep 2, 1999·Alcoholism, Clinical and Experimental Research·P FaddaW Fratta
Sep 24, 1999·International Journal of STD & AIDS·N M Petry
Sep 12, 2000·European Journal of Pharmacology·R CiccocioppoM Massi
Sep 22, 2000·Peptides·R CiccocioppoM Massi
Dec 21, 2000·Current Psychiatry Reports·R E Johnson, J C McCagh
Sep 21, 2001·British Journal of Pharmacology·R LattanziG Improta
Dec 14, 2001·The New England Journal of Medicine·J H KrystalUNKNOWN Veterans Affairs Naltrexone Cooperative Study 425 Group

❮ Previous
Next ❯

Citations

Jun 29, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·M KitayamaD G Lambert
Nov 6, 2013·Pharmacology & Therapeutics·Jeffrey M WitkinRoberto Ciccocioppo
Aug 27, 2011·Journal of Medicinal Chemistry·Gerta Cami-KobeciStephen M Husbands
Aug 2, 2008·Nature Reviews. Drug Discovery·David G Lambert
Aug 29, 2009·The Journal of Pharmacology and Experimental Therapeutics·Taline V KhroyanLawrence Toll
Feb 9, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Talakad G LohithMasahiro Fujita
May 28, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roberto CiccocioppoKoji Teshima
Feb 26, 2010·Expert Opinion on Therapeutic Patents·Tally M Largent-Milnes, Todd W Vanderah
Feb 12, 2008·Trends in Pharmacological Sciences·Rainer Spanagel, Falk Kiefer
Dec 7, 2007·British Journal of Pharmacology·B SpagnoloN T Zaveri
May 26, 2010·CNS Neuroscience & Therapeutics·Girolamo Calo'Remo Guerrini
May 8, 2013·Current Opinion in Neurobiology·Massimo UbaldiRoberto Ciccocioppo
Nov 19, 2014·Addiction Biology·Marcus W Meinhardt, Wolfgang H Sommer
Apr 11, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Shawn M FlynnPaul W Czoty
Jun 22, 2017·Addiction Biology·Marsida KallupiRoberto Ciccocioppo
Nov 11, 2008·Annals of the New York Academy of Sciences·Saturnino SpigaMarco Diana
Jan 1, 2008·Substance Abuse : Research and Treatment·Thomas F KresinaH Westley Clark
Nov 26, 2019·The Journal of Clinical Investigation·Nora D Volkow, Carlos Blanco
Jun 4, 2017·Proceedings of the National Academy of Sciences of the United States of America·Zhana DurenWing Hung Wong
Mar 7, 2021·International Journal of Molecular Sciences·Francesca Felicia CaputiPatrizia Romualdi
Apr 23, 2017·Neuropharmacology·Howard C Becker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.